Background. Sirolimus is an immunosuppressive drug recently developed for organ transplantation. Its mechanism of action, independent of calcineurin, is different from that of cyclosporine and tacrolimus, two calcineurin inhibitors (CIs). Because the toxicity of CIs is partly the result of calcineurin blockade, sirolimus exhibits a different toxicity profile. In this study, we evaluated the profile, frequency, and severity of cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Patients and Methods. A systematic and in-depth evaluation of skin, mucous membranes, nails, and hair was performed in 80 renal transplant recipients receiving sirolimus-based therapy. The mean duration of the graft was 6 years and of sirolimus treatment was 18 months. Mycophenolate mofetil and steroids were combined with sirolimus for 74 patients. Sirolimus was used as first immunosuppressive therapy for 36 patients, and 44 patients were switched from CIs to sirolimus. Results. Seventy-nine patients (99%) experienced cutaneous adverse events. Twenty patients (25%) demonstrated serious adverse events, and six patients (7%) stopped sirolimus during the 3 months after the study because of cutaneous events. The most frequent of these were pilosebaceous apparatus involvement, including acne-like eruptions (46%), scalp folliculitis (26%), and hidradenitis suppurativa (12%); edematous complaints, including chronic edemas (55%) and angioedema (15%); mucous membrane disorders, including aphthous ulceration (60%), epistaxis (60%), chronic gingivitis (20%), and chronic fissure of the lips (11%); and last, nail disorders including chronic onychopathy (74%) and periungual infections (16%). Conclusions. Skin disorders are frequent in renal transplant recipients receiving sirolimus as a long-term therapy. Despite the usually mild nature of skin events, they are often the reason for stopping sirolimus.
S irolimus (rapamycin, Rapamune, Wyeth Europa Ltd, United Kingdom) is a product of Streptomyces hygroscopicus fermentation and was the first drug to be recently licensed in this group of immunosuppressive therapy used in renal transplantation. Its mechanisms of action differ from those of the calcineurin inhibitors (CIs) cyclosporine and tacrolimus. Similar to tacrolimus, sirolimus binds to FKBP12 immunophilin, but instead of CI, it inhibits mammalian target of rapamycin, a key protein kinase involved in the transduction signal of cytokines such as interleukin 2 and growth factors. Sirolimus therefore inhibits the T-lymphocyte proliferation that occurs in response to stimulation by antigens and cytokine (1) . Its immunosuppressive properties, combined with its lack of nephrotoxicity, make it a strong candidate for replacing CI.
Sirolimus has been used combined with CI (2-6) or as immunosuppressive therapy together with steroids, azathioprine, or mycophenolate mofetil (MMF) (7) (8) (9) . A recent phase 3 study demonstrated that sirolimus allows safe and efficient cyclosporine withdrawal as early as 3 months after transplantation (10) . Sirolimus has also been used to replace CI in kidney transplant recipients demonstrating chronic allograft nephropathy to eliminate cyclosporine nephrotoxicity (11) . Its use in other organ transplantations has now been extensively evaluated (12) (13) (14) (15) . Its immunosuppressive properties have also led to trials involving immune diseases such as psoriasis or rheumatoid arthritis (16, 17) . The clinical side effects of sirolimus are mainly asthenia, headache, arthralgia, lymphocele, delayed wound healing, and interstitial pneumonitis (2, 16 -18) . In the field of dermatology, edema, acne, epistaxis, aphthous ulceration, and vasculitis have been mentioned (2, 3, 7, 8, 11, 15, 16, 19 -26) . However, the true incidence, clinical characteristics, and severity of such dermatologic adverse events in patients on sirolimus-based therapy are not known. We therefore conducted a cross-sectional study in renal transplant recipients receiving sirolimus to evaluate more precisely the profile, frequency, and severity of dermatologic adverse events.
METHODS

Patients
From March to June 2003, a dermatologic consultation was proposed to the 95 renal transplant recipients who were receiving sirolimus and being regularly followed in the Department of Adult Renal Transplantation at the Necker Hospital in Paris. Sirolimus was given immediately after transplantation (de novo patients) or after conversion from CI to sirolimus (switched patients). Eighty of the 95 patients (84%) were examined separately by each of two dermatologists (E.M. and C.B.) and included in the study. Patients' characteristics and treatment are reported in Table 1 .
Dermatologic Evaluation Protocol
A protocol for dermatologic evaluation was implemented by using a case report form especially created for the study. It comprised 411 items, including data on patients' history of renal transplantation, immunosuppressive drugs in previous or current use, and current nonimmunosuppressive drugs. Dermatologic history before transplantation (especially skin infections, cancer, edema, acne, oral ulceration, and epistaxis), and before sirolimus introduction for patients switched to sirolimus, was evaluated according to patients' assessments and follow-up report forms. Last, we evaluated patients since they started taking sirolimus. This evaluation always included the skin events usually reported in organ transplant recipients (especially infections, benign tumors and cancers, hair disorders, and skin changes such as hyperpigmentation and xerosis), as well as skin disorders already previously associated with sirolimus (edema, acne, aphthous ulceration, and epistaxis). After this evaluation, a physical examination of the skin, mucous membranes, nails, and hair was performed.
Cutaneous Adverse Events and Serious Adverse Events
As defined by the "International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use" (ICH), cutaneous adverse events are "any cutaneous occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment" (27).
To evaluate the severity of skin events, we identified the serious adverse events (SAEs) as defined by the ICH. Accordingly, we considered SAEs to be events resulting in death, being life-threatening, requiring hospital admission or prolongation of existing hospitalization, or resulting in persistent or significant disability or incapacity (27).
We also investigated the reasons why some patients stopped sirolimus during the 3 months after the dermatologic evaluation.
Statistical Evaluation
The effects on the frequency of skin events of four variables (sex, switch vs. de novo treatment, and associated current immunosuppressive and nonimmunosuppressive agents) were evaluated using the chi-square test. To compare between-group age differences, and the duration of grafts and sirolimus treatment, the unpaired Student t test was used. The differences were considered significant at a P value less than 0.05. Only statistically significant differences are detailed in Tables 1 to 5 .
Declaration of the Cutaneous Adverse Events
As recommended by the ICH (27), cutaneous adverse events were reported in October and November 2003 to the Centre Régional de Pharmacovigilance of the Hôpital Européen Georges Pompidou, in Paris, an adverse drug reaction center. 
RESULTS
Frequency of Cutaneous Adverse Events
All 80 patients except 1 (99%) presented with at least one cutaneous adverse event, the mean being seven events per patient (range: 1-14).
Cutaneous Infections and Pathologies of the Pilosebaceous Apparatus
The frequencies of viral, bacteriologic, and fungal cutaneous infections are reported in Table 2 . The frequencies of infections of the pilosebaceous apparatus are reported in Table 3. Skin eruptions resembling acne developed soon after sirolimus was started (median: 1 month). The skin eruptions were sex-dependent and occurred in 35 men (75% of men) but only 2 women (6% of women, PϽ0.0001). Moreover, one of the two women demonstrated primary amenorrhea without hormonal substitution. These acne-like eruptions were mainly located on the face and trunk, and in 21 cases (53%) they were combined with scalp folliculitis. Retentional components (comedones and cysts) were only present in eight patients (21%), but inflammatory components (papules or pustules) were observed in 35 patients (95%). Nine patients (11%) demonstrated painful impressive nodular acne in the cervical area; in two of them the face was also involved and exhibited severe edema (Fig. 1A) . These nodules were not cystic but inflammatory.
Ten patients (12%) demonstrated hidradenitis suppurativa (Fig. 1B ) located in axillary, perianal, and inguinal areas (nϭ9, 6, and 1, respectively). This was neither sex-dependent nor combined with acne-like eruptions. Surgical excision and antibiotics were required in two cases, antibiotics alone were required in two cases, and local treatments were required in the remaining six cases.
Edemas
Edemas were observed in 52 patients (65%). They consisted of chronic edemas (Ͼ1 month) in 44 patients (55%) and angioedemas in 12 patients (15%). Chronic edemas were defined as edemas present on the day of the examination, lasting more than 1 month, resistant to diuretics, and without local, renal, or cardiac causes. Angioedema was defined as an acute subcutaneous edema that resolved in less than 4 days.
Chronic edemas were located in the lower limbs in 43 of 44 cases (98%). They were soft, noninflammatory edemas. Three kinds of chronic edema were observed: exacerbation of previous edema (group 1, nϭ7), early-onset edema that developed during the month after sirolimus introduction (group 2, nϭ15), and late-onset edema that developed at least 2 months thereafter (group 3, nϭ17). In group 1, six of the seven patients were females (86%, Pϭ0.02). Edemas were always located in the lower limbs, except in one patient who also had edema in one arm. In group 2, early-onset edemas developed soon after sirolimus introduction (median: 3 days). Most patients (80%) had sirolimus as de novo therapy (PϽ0.01), and their edema was always located in the lower limbs. Two patients also demonstrated edema of the upper limbs or eyelids. The 17 patients in group 3 developed edema after a median period of 16 months (2-59 months) of sirolimus treatment. In 11 of these patients (65%), edema occurred after a trauma of the leg (nϭ5), an inflammatory disease (nϭ4), or a local infection (nϭ2). In 14 of 17 cases, these edemas were asymmetric (Pϭ0.04), and in 6 of these 14 cases the edemas were contralateral to the transplant. The edemas developed in the lower limbs in 16 cases, in the eyelids in 4 cases, and in the arms in 4 cases. Two women developed edema in one arm and in the homolateral breast ( Fig. 2A) .
Remarkably, in three patients, edema of the legs led to scleroderma-like lesions (Fig. 2B) with the same clinical features, as follows: An acute phase with sudden onset of edema was followed by rapid involvement of the legs and then noninflammatory diffuse sclerosis of the skin. The lower parts of the legs were thin, despite an edema of the foot and upper part of the leg. The first of these three cases was observed in a 59-year-old woman. Sirolimus was used as first-line therapy. Edema and sclerosis of the legs developed immediately after the graft. In the second case, sirolimus was used as CI replacement therapy in a 41-year-old woman. Six months later, after a leg trauma, she developed asymmetric edema of the legs, and sclerosis occurred the following week. The third case was observed in a 49-year-old man with a 3-month history of edema of the legs who was given sirolimus 10 years after the graft. He immediately developed sclerosis of both legs. Histologic examination of skin biopsies of the lesions of two patients (a skin biopsy was not performed in the third patient) was unspecific, showing dermal sclerosis with a mild dermal inflammatory infiltrate but no vasculitis. Immunologic investigations showed negative results. Scleroderma-like changes resolved 3 months after sirolimus withdrawal in one patient and partially resolved in the two other patients after venous contention. 
Angioedemas
Twelve patients (15%) demonstrated acute, transient, nonpruritic, non-erythematous, local subcutaneous edemas that developed within a few hours and disappeared in 24 hr to 4 days. Only one case of edema of the right hemi-face was documented on the day of the consultation. It had the clinical appearance of an angioedema. The face was the main location (nϭ11), with oral cavity involvement in seven cases (tongue: four; lips: two; palate: one). Initially, angioedemas were onesided (10 cases) and then spread further evenly. In 10 patients they recurred from 2 to 25 times at the same location, but an additional area was involved in two patients (tongue and cheek, and tongue and hand). Steroids had to be used in one case because of severe involvement of the tongue. In other cases, edemas disappeared without any treatment. During angioedemas, six patients were receiving angiotensin-converting enzyme inhibitors (ACEIs) and two patients were receiving angiotensin II receptor antagonists. These eight patients demonstrated recurrent edema of the face, which affected the mucous membranes inside the mouth in five cases. In the remaining patients without ACEI or angiotensin II receptor antagonists, the edemas occurred after physical activity (nϭ1), walnut ingestion (nϭ1), or mango ingestion (nϭ1) in three, and no triggering factor has been identified in one.
Mucous Membrane Pathologies
Aphthous ulcerations were reported by 48 patients (60%) and observed in 10 of them on the day of the evaluation (Table 4) . Aphthous ulcerations were significantly associated with sirolimus switch therapy (Pϭ0.002), developed soon after sirolimus was started (median: 1 week; range: 1 day-15 months), and were more severe during the first 2 months. The oral cavity was concerned in all cases, and anal aphthous ulceration occurred in one case. Recurrent epistaxis, reported by all 48 patients (60%), was the most frequent adverse event affecting the nose. Chronic fissure of the lips and chronic gingivitis were also frequent. Chronic gingivitis was associated with previous cyclosporine treatment in 3 of 16 cases, with current cyclosporine treatment in no case, and with the use of calcium channel blockers in a single case.
Nail and Hair Pathologies
Nail abnormalities occurred in 59 patients (74%). Forty-five patients (56%) complained of fragile nails, 11 patients (14%) demonstrated soft or thin nails, and 8 patients (10%) demonstrated slow growth (Table 4 ). The most frequent clinical abnormalities were longitudinal ridging or fissures, distal onycholysis and erythema, and splinter hemorrhages of the nail plate. For 13 of the 59 patients (22%), onychopathy was complicated by ingrowing nails, chronic perionyxis, or whitlow.
Skin and scalp hair abnormalities were frequent. They mainly comprised diffuse mild alopecia of the scalp and hypertrichosis of the face.
Miscellaneous Cutaneous Adverse Events
The few skin cancers were associated with total graft duration (PϽ0.05). They were epitheliomatous lesions, but no melanoma was observed. Skin changes mainly involved xerosis and fragility. Seven patients (9%) demonstrated hyperpigmentation of the face. Three demonstrated four immune cutaneous adverse events, which developed during sirolimus treatment: psoriasis and alopecia areata in one patient, alopecia areata in one patient, and Henoch-Schönlein purpura in one patient. Five other patients demonstrated acquired acrocyanosis. One of them experienced paroxysms characteristic of Raynaud's phenomenon. These and other cutaneous adverse events are listed in Table 5 .
Serious Adverse Events
Twenty patients (25%) demonstrated 26 cutaneous SAEs. Chronic edema and angioedema (nϭ8 and 2, respectively) were the most frequent. Other SAEs were cutaneous infections (bacterial, including hidradenitis suppurativa and periungual infections, nϭ6; herpes zoster, nϭ2); severe aphthous ulcerations in three patients who were switched from CI to sirolimus; acne (nϭ2); skin cancers (nϭ1); severe epistaxis (nϭ1); and Henoch-Schönlein purpura (nϭ1). Four of these SAEs were considered life threatening. They concerned two patients with transient edema of the tongue, one with epistaxis with severe hemorrhage, and one with severe bilateral hidradenitis suppurativa with multiple furuncles. Twelve patients required hospitalization (four for severe chronic edemas, seven for bacterial infections or herpes zoster, and one for surgical treatment of skin cancers). Three others required extension of their hospital stay for severe aphthous ulcerations, and seven had significant transient disability, including four with chronic edemas, two with severe painful acne, and one with Henoch-Schönlein purpura.
Discontinuation of Sirolimus
Sixteen patients (20%) had to stop sirolimus during the 3 months after the study. Ten patients (12%) stopped because of cutaneous adverse events, either alone (nϭ6) or combined with extracutaneous adverse events (anemia ϩ hypertriglyceridemia, nϭ1, and proteinuria, nϭ3). Four of these 10 patients were switched to tacrolimus, and five patients were switched to cyclosporine. The remaining patient demonstrated end-stage renal failure after severe infection and required dialysis. In four patients, cutaneous adverse events were considered serious (hidradenitis suppurativa with multiple furuncles, nϭ1; severe leg edemas, nϭ2; and severe edemas with scleroderma-like evolution, nϭ1). Other patients demonstrated social or functional disabilities after cutaneous adverse events such as severe acne (nϭ2), recurrent hidradenitis suppurativa (nϭ1), chronic edemas (nϭ4), angioedema (nϭ1), aphthous ulceration (nϭ3), and recurrent epistaxis (nϭ3). Last, six patients stopped sirolimus because of extracutaneous adverse events: pneumopathy (nϭ3), severe anemia (nϭ1), myelodysplasia (nϭ1), or proteinuria (nϭ1).
After sirolimus discontinuation (period of observation without sirolimus: 2-6 months), acne, aphthous ulceration, and epistaxis disappeared in all cases, and hidradenitis suppurativa did not relapse. No episode of angioedema was observed. Chronic edema persisted for 3 months in one patient, partially regressed in one patient (after 8 weeks), and disappeared in the remaining four patients within 2 to 12 weeks. Scleroderma-like lesions resolved after sirolimus was stopped.
DISCUSSION
This cross-sectional protocol and in-depth study of cutaneous adverse events in patients receiving sirolimus-based therapy used as a long-term therapy (mean duration of sirolimus therapy: 18 months) showed that these events were extremely frequent (99% of patients) and sometimes severe (25% of patients). Acne-like eruptions, edemas, xerosis, aphthous ulceration, epistaxis, and nail involvement were the most common. The present results revealed four main cutaneous pathologies observed in these patients: pathologies of the pilosebaceous apparatus (acne-like eruptions, hidradenitis suppurativa, and scalp folliculitis), edematous disorders (chronic edema, scleroderma-like lesions, and angioedema), mucous membrane involvement (aphthous ulceration, recurrent epistaxis, cheilitis, and gingivitis), and nail disorders.
Acne is reported in 2% to 15% of organ transplant recipients and is usually associated with steroid and cyclosporine ingestion (3, 28 -30) . In trials of sirolimus, this frequency was estimated at 15% to 25% (3, 11, 16) . The frequency of acne is still probably underestimated in the literature because only severe acne is generally reported. Approximately half of the present patients demonstrated an acne-like eruption, and it occurred in 75% of the men. This eruption differs from acne vulgaris. The pathogenesis of acne vulgaris combines increased sebum production and ductal hypercornification that induces comedone production. Inflammation and infection then lead to the formation of papules and pustules. Here, in the acne-like eruption associated with sirolimus ingestion, no retentional component was observed. Sebaceous areas were involved, but the lesions frequently extended to the forearm, cervical area, and internal surface of the arm, which in acne vulgaris are usually lesion-free. The high frequency of acne combined with scalp folliculitis found here is unusual. At least in a few cases, we observed severe painful, nodular, edematous lesions (without cysts) at the nape of the neck and on the face. The male predominance of acne-like eruptions suggests that this side effect is hormone dependent.
In renal transplant recipients, the frequency of chronic edemas has been evaluated at 15% to 44% whatever the immunosuppressive treatment (19, 29) . It is probably underreported, because it is generally imputed to renal dysfunction but not to the treatments. In studies with sirolimus, chronic edemas have been reported in 8% to 62% of transplant recipients (11, 15, 19 -21, 26) . In the present study, chronic edemas affected 55% of the population. The high frequencies of local traumatisms associated with acquired edemas in our study indicate that sirolimus may be one of the causes of edemas. The sirolimus-FKBP12 complex inhibits the growth of vascular smooth-muscle cells (31, 32) . It might involve the entire arterial network, thus altering local blood pressures and increasing edema formation. In addition, sirolimus reduces the production of vascular endothelial growth factor (33) , which in turn might affect local vascular permeability and favor the occurrence of edemas. Two patients with psoriasis, who were receiving sirolimus, were recently reported to have peripheral edemas linked to capillary leak syndrome (34) . Sirolimus promotes prostacyclin release, which may have been involved in the vasodilatation of these patients.
We observed angioedemas in 12 patients (15%), mainly on the face. In some cases, foods or sport activity may have triggered edema formation. Angioedemas associated with ACEI have been reported in organ transplant recipients. They may develop at any time from a few hours to many years after ACEI introduction (35, 36) . Their prevalences are estimated at approximately 1% and 5% in renal and cardiac transplant recipients, respectively, receiving ACEI (i.e., cyclosporine-azathioprinebased therapy) versus 0.1% to 0.5% in the general population (35) (36) (37) . We cannot exclude the possibility that ACEI induced angioedema in 6 of the 28 patients receiving this medication (21%). Finally, in all patients except one, a cause was suspected in the pathogenesis of angioedemas. In these patients, sirolimus may have increased the incidence of angioedemas Mucous membrane involvement is frequent in patients receiving sirolimus, probably because of its direct toxic effect on oral and nasal mucous membranes. Thus, aphthous ulcerations or oral ulcerations have been reported in 10% to 100% of sirolimus-treated patients (2, 3, 7, 8, 11, 15, 16, 22, 23) . The great variability of the frequency of such complaints may be attributable to various factors, including the presence of underlying conditions such as organ transplantation, psoriasis, and diabetes mellitus, the care given to the search for lesions, the way they were described (herpes, aphthous ulceration, oral erosions, or ulcerations), and the treatment protocols used. Mouth ulcers usually occur just after the introduction of sirolimus treatment. The higher frequency and severity of aphthous ulceration after a switch from CI to sirolimus (here, the aphthous ulceration of three patients who were switched from CI to sirolimus was considered as an SAE) may have two explanations: (1) When used de novo, immediately after transplantation, antiviral prophylaxis with valacyclovir and high-dose steroids may be responsible for the absence of viral or inflammatory cofactors, and (2) longstanding immunosuppressive therapy might induce mucous membrane fragility enhanced by sirolimus (23, 28) . In regard to epistaxis, this has been reported in less than 15% of organ transplant recipients receiving sirolimus (2, 20) , but in our study, 48 patients (60%) experienced at least one nosebleed. Systematic evaluation of this adverse event in our study population may explain this higher frequency.
In this population, we observed a particular form of monomorphic onychopathy. It combined slow growth and thin nails with distal onycholysis, erythema, and longitudinal ridging. The nail fragility probably increased the risk of splinter hemorrhages of the nail plate and of periungual traumatisms, which lead to chronic perionyxis and infections. Some authors have reported that onycholysis complicates chemotherapy and also in a few cases the use of MMF in organ transplantation (39, 40) . Recently, nail disorders have been reported in 56% of renal transplant recipients. They consisted mainly of onychomycosis (13%), leukonychia (21%), absence of lunula (17%), and longitudinal ridging (12%) (41) .
It is difficult to attribute adverse events after organ transplantation to immunosuppressive drugs. Is one particular drug responsible or a drug combination? Are these events directly imputable to the drug's action or to the resulting immunosuppression? A sirolimus trial including a control group without sirolimus, with a dermatologic evaluation blinded for immune suppression, matched for sex, age, immune suppression, and graft duration, might help to answer these questions. Sixty-nine of our 80 patients (86%) received the same combination of sirolimus, MMF, and steroid. We cannot exclude the possibility that some adverse events were imputable to MMF or to the previous combination. However, MMF has never been incriminated in acne-like eruptions, chronic edemas, scleroderma-like evolution, angioedema, or epistaxis, although its role in severe stomatitis and onycholysis was recently considered (38, 39) . Nevertheless, such conditions remain rare in patients receiving MMF-based therapy. Moreover, as far as we know, such a high frequency of these cutaneous adverse events has never been reported after organ transplantation, and some events, including scleroderma-like evolution of edemas and onychopathy, have never been reported thereafter at all. However, such a systematic in-depth study after organ transplantation has never been published in organ transplantation. These considerations suggest that either sirolimus or its combination with MMF is directly responsible for the pathogenesis of these cutaneous adverse events.
Although most cutaneous adverse events are mild, they are often the reason for stopping sirolimus, either because a few of them are serious or because of their social and functional effects. The identification of groups of pathologies that might have the same pathogenesis leads one to consider novel properties for sirolimus.
